Clinical Application Value of Paclitaxel Combined with Cisplatin Neoadju-vant Chemotherapy in Non-surgical Treatment of Locally Advanced Cer-vical Cancer
Objective To evaluate the clinical effect of paclitaxel combined with cisplatin neoadjuvant chemotherapy in non-surgical treatment of locally advanced cervical cancer.Methods A total of 92 patients with locally advanced cervical cancer who were admitted to the Department of Obstetrics and Gynecology of Daye People's Hospital of Hu-bei Province from January 2016 to January 2019 were conveniently selected as the study objects and divided into ob-servation group(46 cases)and control group(46 cases)according to the random number table method.The observation group was treated with cisplatin neoadjuvant chemotherapy combined with concurrent chemotherapy,while the control group was treated with simultaneous chemotherapy alone.The effect of intervention was compared.Results The effec-tive rate of observation group(65.21%)was higher than that of control group(43.49%),the difference was statistically significant(χ2=4.380,P<0.05).There were no significant differences in carcinoembryonic antigen(CEA)and carbohy-drate antigen 15-3(CA15-3)between the two groups before treatment(t=0.120,0.102,both P<0.05).After treatment,the levels of CEA and CA15-3 in the observation group were significantly lower than those in the control group,the differences were statistically significant(t=9.567,13.880,both P<0.05).There was no significant difference in the in-cidence of adverse reactions between the two groups(χ2=0.109,P<0.05).The 3-year survival rate was 63.04%in the observation group,higher than 39.13%in the control group,the difference was statistically significant(P<0.05).The median survival time of the observation group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion Paclitaxel combined with cisplatin neoadjuvant chemotherapy in the treatment of non-surgical patients with locally advanced cervical cancer can achieve satisfactory efficacy,which is conducive to improving the level of tumor markers,with good safety,and can improve the 3-year survival rate and me-dian survival time of patients,which is worthy of clinical promotion.
万方数据
维普
